337 results on '"Fazli, L."'
Search Results
2. Regulation of c-Myc expression by the histone demethylase JMJD1A is essential for prostate cancer cell growth and survival
3. Prognostic value of Ki67 in localized prostate carcinoma: a multi-institutional study of > 1000 prostatectomies
4. The role of DAB2IP in androgen receptor activation during prostate cancer progression
5. Fibroblast growth factor and ornithine decarboxylase 5′UTRs enable preferential expression in human prostate cancer cells and in prostate tumors of PTEN−/− transgenic mice
6. Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E
7. Lentiviruses with trastuzumab bound to their envelopes can target and kill prostate cancer cells
8. Targeting and killing of prostate cancer cells using lentiviral constructs containing a sequence recognized by translation factor eIF4E and a prostate-specific promoter
9. Trop-2 is up-regulated in invasive prostate cancer and displaces FAK from focal contacts
10. 619P Immune profiling of advanced prostate cancer harbouring homologous recombination deficiency
11. Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort
12. Evaluation of ERG and SPINK1 by immunohistochemical staining and clinicopathological outcomes in a multi-institutional radical prostatectomy cohort of 1067 patients
13. A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer
14. The role of homeostatic regulation between tumor suppressor DAB2IP and oncogenic Skp2 in prostate cancer growth
15. 355 - Head-to-head comparison of efficacy of darolutamide (ODM-201) vs. enzalutamide on mutated forms of the androgen receptor
16. 916P - Biological assessment of viable germ cell tumor (VT) in patients (pts) with seminoma (S) and non-seminoma (S) using miR371
17. 747 - Targeting enzalutamide-resistant prostate cancer using the novel androgen receptor inhibitor ODM-201
18. 390 - Tumor regression grading after neoadjuvant chemotherapy in bladder cancer: Validation in an independent cohort
19. 972 - T-DM1, a novel HER2 antibody-cytotoxic drug conjugate, has anti-metastatic potential and is a promising targeted therapy for bladder cancer with HER2 IHC score 2+/3+
20. 849 - Targeting heat-shock protein 27 enhances sensitivity to sorafenib treatment in renal cancer in vitro and in vivo
21. 1046 Evaluation of carbonic anhydrase IX as a potential therapeutic target in urothelial carcinoma
22. 929 Targeting lactate transporters for the treatment of urothelial carcinoma
23. Evaluation of a Novel Quantitative Digital Pathology Technique as a Tool for Predicting Prostate Cancer Recurrence
24. 63 Erythropoietin accelerates the regeneration of ureteral function in a murine model of obstructive uropathy
25. 802 A role for the hedgehog effector Gli1 in mediating stent-induced ureteral aperistalsis and smooth muscle dysfunction
26. 522 Targeting HER2 with trastuzumab-DM1 (T-DM1) is highly effective in preclinical models of HER2-overexpressing bladder cancer
27. 516 Targeting IGF-BP2 and 5 with the bispecific antisense oligodeoxynucleotide OGX-225 in chemoresistant bladder cancer
28. 403 Patient-derived primary xenografts in the preclinical development of novel targeted therapies for bladder cancer
29. 39 Notch2 promotes bladder cancer progression: Pre-clinical rationale for a novel targeted therapy
30. Fibroblast growth factor and ornithine decarboxylase 5′UTRs enable preferential expression in human prostate cancer cells and in prostate tumors of PTEN−/− transgenic mice.
31. 235 Clusterin knockdown synergizes activity of second generation anti-androgen, MDV3100, through enhancing AR degradation and repression of FKBP52 in castrate resistant prostate cancer model
32. 236 The combination of carbidopa plus bicalutamide suppresses androgen-receptor transactivation, induces apoptosis and delays castration-resistant prostate cancer progression
33. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer.
34. MP-03.04 The Combination Treatment of Bicalutamide Plus Carbidopa Significantly Enhances the in vivo Antitumor Activity on LNCaP Castration-resistant Prostate Cancer Xenograft Tumors Compared To Single Use of Each Drug
35. Integrin-linked kinase, a promising cancer therapeutic target: biochemical and biological properties
36. Protein Expression of PTEN, Insulin-Like Growth Factor I Receptor (IGF-IR), and Lethal Prostate Cancer: A Prospective Study
37. 791 Notch2-HEY axis promotes tumour growth in bladder cancer through cell cycle progression and de-differentiation.
38. 209 A phase 1 clinical trial assessing an intravesical administered second-generation antisense oligonucleotide targeting heat shock protein 27 in bladder cancer.
39. 138 Exploring a novel therapeutic target for neuroendocrine prostate cancer using a xenograft model of trans-differentiation.
40. Multi-scale relational graph convolutional network for multiple instance learning in histopathology images.
41. Author Correction: IRE1α-XBP1s pathway promotes prostate cancer by activating c-MYC signaling.
42. Prostate Cancer Risk Stratification by Digital Histopathology and Deep Learning.
43. PDIA2 has a dual function in promoting androgen deprivation therapy induced venous thrombosis events and castrate resistant prostate cancer progression.
44. Loss of feedback regulation between FAM3B and androgen receptor driving prostate cancer progression.
45. A novel type-2 innate lymphoid cell-based immunotherapy for cancer.
46. DPYSL5 is highly expressed in treatment-induced neuroendocrine prostate cancer and promotes lineage plasticity via EZH2/PRC2.
47. Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trial.
48. RNF185 Control of COL3A1 Expression Limits Prostate Cancer Migration and Metastatic Potential.
49. Semaphorin 3C promotes de novo steroidogenesis in prostate cancer cells.
50. Artificial Intelligence-Based PTEN Loss Assessment as an Early Predictor of Prostate Cancer Metastasis After Surgery: A Multicenter Retrospective Study.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.